FDA panel backs Gilead’s Truvada to prevent HIV

WASHINGTON (Reuters) – A U.S. Food and Drug Administration panel of outside experts recommended Gilead Sciences Inc’s Truvada as a treatment for preventing HIV infection among people at risk for contracting AIDS, including homosexual and bisexual men. In a move that could lead to a new milestone for treatment in the evolution of the worldwide AIDS epidemic, the FDA advisory committee voted 19-3 to endorse the drug’s use for controlling HIV infection among the highest risk group – men who have sex with men. …